Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bedinvetmab (Librela/Beransa) in dogs raises safety concerns, including rapidly progressive osteoarthritis, and warrants vigilant adverse event reporting.

Journal of the American Veterinary Medical Association·2026
Same author

Biomechanical Analysis of Orthogonal Plating and Plate-Rod Combination in a Canine Tibial Fracture Gap Model.

Veterinary and comparative orthopaedics and traumatology : V.C.O.T·2026
Same author

Lectin Microarray-based Glycomics and Machine Learning Identify Shared Osteoarthritis Biomarkers in Humans, Dogs, and Horses.

bioRxiv : the preprint server for biology·2025
Same author

Serum Anti-Drug Antibodies in Psoriasis Patients Undergoing Biologic Therapy in Real-World Clinical Practice: A Single-Center Retrospective Study.

The Journal of dermatology·2025
Same author

Canine Haemophilic Arthropathy: Magnetic Resonance Imaging and Histologic Assessment of Joints in Two Adult Beagles with Confirmed Factor Deficiencies.

Veterinary and comparative orthopaedics and traumatology : V.C.O.T·2025
Same author

Pathogenesis of Pseudocheckerboard Pattern in Mechanic's Hands.

The Journal of dermatology·2025

Related Experiment Video

Updated: Nov 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K

Psoriasis: Recent progress in molecular-targeted therapies.

Masaru Honma1,2, Kei Hayashi2

  • 1Department of Dermatology, Asahikawa Medical University Hospital, Asahikawa, Japan.

The Journal of Dermatology
|January 6, 2021
PubMed
Summary

Psoriasis, a chronic inflammatory skin condition, is now effectively managed with advanced molecular-targeted therapies. These treatments, including biologics, significantly improve symptoms and patient quality of life by targeting key disease pathways.

Keywords:
IL-17IL-23IL-36JAKPDE4RORγTTNFbiologicscytokinesmolecular mechanismpsoriasispsoriatic arthritissmall-molecule inhibitors

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

707

Related Experiment Videos

Last Updated: Nov 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

707

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a chronic, inflammatory skin disease causing scaly plaques on common sites like the scalp and extremities.
  • It significantly impacts patient quality of life and is often associated with comorbidities like psoriatic arthritis.

Purpose of the Study:

  • To review the advancements in molecular-targeted therapies for psoriasis.
  • To highlight the understanding of psoriasis pathogenesis, particularly the IL-23/IL-17 axis.
  • To emphasize the importance of this knowledge for refining treatment strategies.

Main Methods:

  • Review of recent molecular-targeted therapies for psoriasis.
  • Analysis of the role of the IL-23/IL-17 axis and Th17 cells in pathogenesis.
  • Evaluation of clinical effects and patient quality of life improvements.

Main Results:

  • Molecular-targeted therapies, including biologics and small-molecule inhibitors, offer excellent treatment for severe psoriasis and psoriatic arthritis.
  • These therapies have led to significant symptom alleviation and improved patient quality of life.
  • The IL-23/IL-17 axis, driven by Th17 cells, is identified as a crucial pathogenic pathway.

Conclusions:

  • Understanding the molecular mechanisms and therapeutic targets is vital for managing psoriasis.
  • Advanced therapies targeting specific molecules have revolutionized psoriasis treatment.
  • Continued research into molecular pathways will enable more refined and personalized therapeutic strategies.